Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Non-Current Liabilities (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $97.1 million as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities fell 31.83% year-over-year to $97.1 million; the TTM value through Mar 2026 reached $97.1 million, down 31.83%, while the annual FY2025 figure was $106.6 million, 34.48% down from the prior year.
  • Total Non-Current Liabilities hit $97.1 million in Q1 2026 for Bicycle Therapeutics, down from $106.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $229.7 million in Q2 2023 and bottomed at $97.1 million in Q1 2026.
  • Average Total Non-Current Liabilities over 5 years is $159.2 million, with a median of $159.8 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities soared 75.6% in 2023 and then plummeted 34.48% in 2025.
  • Bicycle Therapeutics' Total Non-Current Liabilities stood at $136.0 million in 2022, then soared by 61.65% to $219.8 million in 2023, then dropped by 26.0% to $162.7 million in 2024, then crashed by 34.48% to $106.6 million in 2025, then dropped by 8.9% to $97.1 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $97.1 million, $106.6 million, and $144.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.